Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prostate Cancer Detected in Blood Using Flow Cytometry

By LabMedica International staff writers
Posted on 22 Feb 2016
Current methods of detecting prostate cancer, such as the prostate-specific antigen (PSA) test and biopsies, have limitations. More...
PSA tests are based on measuring a specific protein released by the prostate gland, but do not provide a definitive diagnosis.

A physical exam and biopsy are needed if PSA levels are elevated; however, even the painful biopsy procedure has a 15% error rate. During biopsies, a painful and invasive procedure, 12 needles are inserted into the rectum, with the hope of extracting material from an area with a tumor.

A team of scientists at the Western University's Schulich School of Medicine and Dentistry (London, ON, Canada) and at Lawson Health Research Institute (London, ON, Canada) have repurposed a machine once used to detect airborne pathogens in the second Gulf War. The machine is now used for fluid biopsies, a noninvasive way to detect prostate microparticles in the blood in a matter of minutes. Microparticles are essentially refuse released by prostate cells that circulate throughout the bloodstream.

The machine was used in the Gulf War, and more commonly to test water purity and the machine uses flow cytometry (Apogee Flow Systems; Hemel Hempstead, UK) to detect microparticles. Flow cytometry measures the specific characteristics of a fluid, such as blood, as it passes through a laser. Most men, who are more than 40 years old, regardless of their health, have detectable levels of prostate microparticles in their bloodstream. The scientists have conducted the first clinical cancer project to correlate the number of microparticles in the blood to the risk of having prostate cancer in that the more microparticles, the higher the risk.

The study provides a more accurate and less invasive testing method for patients suspected of having prostate cancer, and helps to identify patients who are at a higher risk of dying from prostate cancer. Hon Leong, PhD, an assistant professor and team leader, said, “Our findings point to a new direction in how we can better identify patients who actually have prostate cancer. With this test, we can improve the clinical outcomes for patients, reducing costs for unnecessary procedures and reducing errors in diagnosis.”

Related Links:

Western University's Schulich School of Medicine and Dentistry
Lawson Health Research Institute
Apogee Flow Systems



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.